A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver - Related Studies

A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver

This study has been completed.

Study NCT00001587. Last updated on March 3, 2008. Information provided by National Institutes of Health Clinical Center (CC)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Liver Neoplasms
		Neoplasm Metastasis

2	Additional conditions recognized in this trial
		Neoplasms

3	More general conditions related to this trial
		Digestive System Diseases
		Digestive System Neoplasms
		Liver Diseases
		Neoplasms by Site
		Neoplastic Processes
		Pathologic Processes

4	Interventions listed in this trial
		Melphalan

5	More general drug interventions related to this trial
		Alkylating Agents
		Antineoplastic Agents
		Antineoplastic Agents, Alkylating
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Myeloablative Agonists
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

6	Sponsors listed in this trial
		National Cancer Institute (NCI)